Sunday July 23rd 2017

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

Conclusions: Ofatumumab (up to 700 mg) given 2 weeks apart was not associated with any unexpected safety concerns and was well tolerated in patients with RRMS. MRI data suggest a clinically meaningful effect of ofatumumab for all doses studied. Results warrant further exploration of ofatumumab in RRMS. Classification of evidence: This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions. (Source: Neurology)

More – 

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

Leave a Comment

More from category

Mothers who breastfeed might have lower multiple sclerosis risk
Mothers who breastfeed might have lower multiple sclerosis risk

(Reuters Health) - Women who breastfeed may have a lower risk of developing multiple sclerosis later in life compared [Read More]

Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds
Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds

(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain [Read More]

Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs
Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs

MULTIPLE sclerosis - commonly abbreviated to MS - is a type of autoimmune disease which can cause problems with vision, [Read More]

National Patient-Advocacy Organizations Oppose ACA Repeal
National Patient-Advocacy Organizations Oppose ACA Repeal

/About-the-Society/News/National-Patient-Advocacy-Organizations-Oppose-ACA [Read More]

Exclusive: Nurses reluctant to discuss disability with MS patients
Exclusive: Nurses reluctant to discuss disability with MS patients

Nearly two-thirds of specialist nurses are reluctant to discuss disability with patients who have multiple sclerosis, [Read More]